Jump to main navigation | Jump to sub navigation | Jump to SiteMap | Jump to Home Page |

Search | Disclaimer | Accessibility | Rule 26 | Site map |

Minster Pharmaceuticals

Our Therapeutic Focus

Minster Home Page
Migraines
For some they are frustrating and infrequent, but for others they are a daily experience with a major negative impact on the quality of life.......
Minster - Read More
Schizophrenia
Is a major psychiatric disease which affects millions. Management of progressive cognitive decline is recognised as a major unmet need.. ...

Our Products

Minster - Home Page Thumb
Minster - Home Page Thumb
Tonabersat
Is from a new selective class of drugs called neuronal gap junction blockers, with real potential in the prevention of migraine...
Minster - Home Page Thumb
Sabcomeline
Offering a new approach to the treatment of cognitive decline in schizophrenia...
Minster - Home Page Thumb

News and features

30 June 2009
Rajinder Kumar to advise on the development pathways
Minster Pharmaceuticals plc (AIM: MPM) is delighted to announce that one of the most experienced executives in the commercialisation of CNS products, Dr Rajinder Kumar, is joining the Company as a consultant.
Read More News

News and features